Bavarian Nordic Completes Share Buy-Back Program Transactions

COPENHAGEN, Denmark, September 21, 2026 /CourierPR/ -- Bavarian Nordic, a global vaccine company, has announced the completion of transactions under its share buy-back program launched on September 1, 2026. The program, which is executed in accordance with Regulation (EU) No. 596/2014 (as amended) of the European Parliament and of the Council on market abuse and Commission Delegated Regulation (EU) 2016/1052, aims to repurchase shares worth up to DKK 250 million over the period from September 1, 2026, to October 30, 2026.

Since the last announcement on September 14, 2026, Nordea has executed transactions on behalf of Bavarian Nordic. The details of these transactions are published on bavarian-nordic.com. Following these transactions, Bavarian Nordic now holds a total of 3,959,913 treasury shares, which correspond to 4.996% of the Company’s share capital.

Bavarian Nordic, headquartered in Denmark, is a global vaccine company dedicated to improving public health through innovative vaccines. The company is a preferred supplier of mpox and smallpox vaccines to governments and has a leading portfolio of travel vaccines. The share buy-back program is part of the company’s ongoing efforts to optimize its capital structure and enhance shareholder value.

The transactions under the share buy-back program are a significant move for Bavarian Nordic, reflecting the company’s commitment to managing its capital structure and enhancing shareholder value. The program is designed to repurchase shares up to a maximum value of DKK 250 million, and the transactions are being executed in compliance with the Safe Harbour Regulation, which includes Regulation (EU) No. 596/2014 and Commission Delegated Regulation (EU) 2016/1052.

The company’s share buy-back program is part of its broader strategy to optimize its capital structure and enhance shareholder value. By repurchasing shares, Bavarian Nordic aims to reduce the number of outstanding shares, potentially increasing the value of the remaining shares. The transactions executed by Nordea as of the latest update are detailed on the company’s website, providing transparency and accountability to shareholders.

Bavarian Nordic’s commitment to public health and its innovative vaccine portfolio continue to position it as a leader in the global vaccine market. The company’s efforts to optimize its capital structure through the share buy-back program are in line with its strategic goals and reflect its dedication to long-term value creation for its shareholders.